Summary:
- Solid Biosciences, a biotechnology company, has reported its financial results for the fourth quarter and full year of 2024.
- The company's lead product candidate, SGT-001, is a gene therapy for the treatment of Duchenne muscular dystrophy (DMD), a rare and fatal genetic disorder.
- Solid Biosciences highlighted progress in its clinical development program for SGT-001, including patient enrollment, safety data, and continued advancement towards potential regulatory approval.